Zobrazeno 1 - 10
of 197
pro vyhledávání: '"Melanoma/*pathology"'
Add Expert Analysis of Difficult Cases to Your Practice With Consultant PathologySuperficial Melanocytic Pathology provides expert guidance for resolving the real world problems pathologists face when diagnosing melanomas and other atypical pigmented
Autor:
Jeremić Jelena, Jović Marko, Stojanović Marina, Mihaljević Jovan, Radenović Kristina, Radosavljević Ivan, Jovanović Milan
Publikováno v:
Srpski Arhiv za Celokupno Lekarstvo, Vol 150, Iss 9-10, Pp 533-538 (2022)
Introduction/Objective. Epidemiology of melanoma including the number of new cases and mortality have been established in most developed countries, but data on pathohistological features are mostly missing. The objective of the study was to investiga
Externí odkaz:
https://doaj.org/article/66da08804ac44c80b30cd16353c927c3
Publikováno v:
Cancer discovery. 13(6):1364-1385
Understanding the evolutionary pathways to metastasis and resistance to immune-checkpoint inhibitors (ICI) in melanoma is critical for improving outcomes. Here, we present the most comprehensive intrapatient metastatic melanoma dataset assembled to d
Autor:
van Zeijl, Michiel C T, van Breeschoten, Jesper, de Wreede, Liesbeth C, Wouters, Michel W J M, Hilarius, Doranne L, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan Willem B, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S, Stevense-den Boer, Marion A, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Boers-Sonderen, Marye J, Suijkerbuijk, Karijn P M, Haanen, John B A G, van den Eertwegh, Alfons J M
Publikováno v:
Journal of Immunotherapy (1997), 46, 197-204
van Zeijl, M C T, van Breeschoten, J, de Wreede, L C, Wouters, M W J M, Hilarius, D L, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Suijkerbuijk, K P M, Haanen, J B A G & van den Eertwegh, A J M 2023, ' Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands ', Journal of Immunotherapy, vol. 46, no. 5, pp. 197-204 . https://doi.org/10.1097/CJI.0000000000000468
Journal of Immunotherapy (1997), 46, 5, pp. 197-204
Journal of Immunotherapy, 46(5), 197-204. Lippincott Williams and Wilkins
Journal of Immunotherapy, 46(5), 197-204. Lippincott Williams & Wilkins
van Zeijl, M C T, van Breeschoten, J, de Wreede, L C, Wouters, M W J M, Hilarius, D L, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Suijkerbuijk, K P M, Haanen, J B A G & van den Eertwegh, A J M 2023, ' Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands ', Journal of Immunotherapy, vol. 46, no. 5, pp. 197-204 . https://doi.org/10.1097/CJI.0000000000000468
Journal of Immunotherapy (1997), 46, 5, pp. 197-204
Journal of Immunotherapy, 46(5), 197-204. Lippincott Williams and Wilkins
Journal of Immunotherapy, 46(5), 197-204. Lippincott Williams & Wilkins
Item does not contain fulltext In phase III trials, ipilimumab plus nivolumab combination therapy is highly efficacious for advanced melanoma, despite many treatment-related grades 3-4 adverse events. Here, we report real-world safety and survival ou
Publikováno v:
Acta Clinica Croatica, Vol 56., Iss 2., Pp 323-330 (2017)
Oral melanoma (OM) occurs from activated or genetically altered epidermal melanocytes. There is no scientific evidence that OM can be linked to physical, chemical and thermal irritation, or to other risk factors of the oral cavity. According to fi gu
Externí odkaz:
https://doaj.org/article/11f89d1051e84ce1945423e62efbb4eb
Autor:
Joshua M. Weiss, Miranda V. Hunter, Nelly M. Cruz, Arianna Baggiolini, Mohita Tagore, Yilun Ma, Sandra Misale, Michelangelo Marasco, Theresa Simon-Vermot, Nathaniel R. Campbell, Felicity Newell, James S. Wilmott, Peter A. Johansson, John F. Thompson, Georgina V. Long, John V. Pearson, Graham J. Mann, Richard A. Scolyer, Nicola Waddell, Emily D. Montal, Ting-Hsiang Huang, Philip Jonsson, Mark T.A. Donoghue, Christopher C. Harris, Barry S. Taylor, Tianhao Xu, Ronan Chaligné, Pavel V. Shliaha, Ronald Hendrickson, Achim A. Jungbluth, Cecilia Lezcano, Richard Koche, Lorenz Studer, Charlotte E. Ariyan, David B. Solit, Jedd D. Wolchok, Taha Merghoub, Neal Rosen, Nicholas K. Hayward, Richard M. White
Publikováno v:
Weiss, J M, Hunter, M V, Cruz, N M, Baggiolini, A, Tagore, M, Ma, Y, Misale, S, Marasco, M, Simon-Vermot, T, Campbell, N R, Newell, F, Wilmott, J S, Johansson, P A, Thompson, J F, Long, G V, Pearson, J V, Mann, G J, Scolyer, R A, Waddell, N, Montal, E D, Huang, T H, Jonsson, P, Donoghue, M T A, Harris, C C, Taylor, B S, Xu, T, Chaligné, R, Shliaha, P V, Hendrickson, R, Jungbluth, A A, Lezcano, C, Koche, R, Studer, L, Ariyan, C E, Solit, D B, Wolchok, J D, Merghoub, T, Rosen, N, Hayward, N K & White, R M 2022, ' Anatomic position determines oncogenic specificity in melanoma ', Nature, vol. 604, pp. 354-361 . https://doi.org/10.1038/s41586-022-04584-6
Nature
Nature
Oncogenic alterations to DNA are not transforming in all cellular contexts1,2. This may be due to pre-existing transcriptional programmes in the cell of origin. Here we define anatomic position as a major determinant of why cells respond to specific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b39395de5cccb872bc76acd0f99b36d
https://portal.findresearcher.sdu.dk/da/publications/fc93f265-733a-47a2-81d0-e175a3bb1f60
https://portal.findresearcher.sdu.dk/da/publications/fc93f265-733a-47a2-81d0-e175a3bb1f60
Autor:
Nadia C.W. Kamminga, Astrid A.M. van der Veldt, Margot C.W. Joosen, Karlijn de Joode, Arjen Joosse, Dirk J. Grünhagen, Tamar E.C. Nijsten, Marlies Wakkee, Marjolein Lugtenberg
Publikováno v:
The British Journal of Dermatology, 187(3), 381-391. Wiley-Blackwell
British Journal of Dermatology, 187(3), 381-391. Wiley-Blackwell Publishing Ltd
British Journal of Dermatology, 187(3), 381-391. Wiley-Blackwell Publishing Ltd
Background Immune checkpoint inhibitors (ICIs) have significantly improved the overall survival of patients with metastatic melanoma. It is unclear how the growing group of metastatic melanoma survivors resume their lives after treatment, and which n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adf72e770b0493dd87aa020b2eee1cb8
https://research.tilburguniversity.edu/en/publications/69f9498d-5186-4d84-a06d-47efa117608e
https://research.tilburguniversity.edu/en/publications/69f9498d-5186-4d84-a06d-47efa117608e
Autor:
Marco Zezza, Nelly Pitteloud, Haithem Chtioui, Laura Marino, Faiza Lamine, Carine Mekoguem, Christophe Kosinski
Publikováno v:
BMC Endocrine Disorders, Vol 19, Iss 1, Pp 1-5 (2019)
BMC Endocrine Disorders
BMC endocrine disorders, vol. 19, no. 1, pp. 144
BMC Endocrine Disorders
BMC endocrine disorders, vol. 19, no. 1, pp. 144
BackgroundThe use of immune checkpoint inhibitor (ICI) therapy is becoming a standard of care for several cancers. Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) or its ligand (PD-
Autor:
Florence Granel-Brocard, Alain Dupuy, D. Legoupil, Jean-Jacques Grob, Marie Beylot-Barry, Marie-Thérèse Leccia, Jean-Philippe Arnault, Florence Brunet-Possenti, A. Bardet, Pierre-Emmanuel Stoebner, Céleste Lebbe, Stéphane Dalle, Eve Maubec, Clara Allayous, Isabelle Borget, Bernard Guillot, Brigitte Dréno, Julie DeQuatrebarbes, Philippe Saiag, Laurent Mortier, Marguerite Kandel, Sophie Dalac, Caroline Dutriaux, Thierry Lesimple, Stefan Michiels, Henri Montaudié, François Aubin
Publikováno v:
Cancer
Cancer, 2020, 126 (3), pp.611-618. ⟨10.1002/cncr.32554⟩
Cancer, Wiley, 2020, 126 (3), pp.611-618. ⟨10.1002/cncr.32554⟩
Cancer, 2020, 126 (3), pp.611-618. ⟨10.1002/cncr.32554⟩
Cancer, Wiley, 2020, 126 (3), pp.611-618. ⟨10.1002/cncr.32554⟩
International audience; Background: Significant progress was recently observed in the treatment of metastatic melanoma (MM). With >50% of patients now reaching a second line of treatment and a significant improvement in the survival rate, an assessme
Autor:
Aymeric Auger, Laura Santambrogio, Patricia Corthésy, Davide Demurtas, Emanuela Romano, Melody A. Swartz, Lambert Potin, Maurice Matter, Cristina C. Clement, Romain Hamelin, Alexandre Harari, Daniel E. Speiser, Natacha Bordry, Lea Maillat, Maria A. S. Broggi
Publikováno v:
The Journal of Experimental Medicine
The Journal of experimental medicine, vol. 216, no. 5, pp. 1091-1107
The Journal of experimental medicine, vol. 216, no. 5, pp. 1091-1107
Identifying cancer biomarkers is of great interest for patient prognosis and monitoring. However, tumor-associated factors are diluted in blood and challenging to detect. Broggi et al. show that lymphatic exudate, accessible at the time of lymphadene